TARGETED THERAPY AFTER PROGRESSION OF HER-2-POSITIVE BREAST CANCER


Citar

Texto integral

Resumo

The review discusses the problem of further application of targeted therapy with trastuzumab in patients with progressive HER2-positive breast cancer (BC). An analysis of numerous studies has shown that against the background of progression, continuation of therapy with trastuzumab with replacement of its combinatorial drug lead to significant improvement of results of treatment of patients with breast cancer with HER2 overexpression. This concept formed the basis of the NCCN recommendations for chemotherapy of HER2-positive metastatic BC in 2009, and since then has not changed significantly.

Bibliografia

  1. Cемиглазов В.Ф., Семиглазов В.В. Значение Герцептина в таргетной адъювантной терапии рака молочной железы // Фарматека, 2007. № 18. С. 8-11.
  2. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-10.
  3. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;Sep15;6:225.
  4. Del Bianco S, Rondinelli R. Trastuzumab-containing therapies: activity beyond disease progression in m.b.c. - a pivotal experience. Proc Am Soc Clin Oncol 2006;24:abstr.10788.
  5. Morabito A, Longo R, Gattuso D, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncology Reports 2006;16:393-8.
  6. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853-8.
  7. Bachelot T, Mauriac L, Delcambre C, et al. Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with her2-positive metastatic breast cancer beyond disease progression. Proc Am Soc Clin Oncol 2007;25:abstr.1094.
  8. Modi S, Stopeck A, Kinden H, et al. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with her2-positive trastuzumab-refractory metastatic breast cancer (mbc): phase 2 trial. Breast Cancer Res Treat 2007;106(Suppl. 1):abstr.6066.
  9. Von Minckwitz G, Du bois A, Schmidt M, et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
  10. Swaby R, Blackwell K, Jiang Z, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. In: 2009 ASCO Annual Meeting. J Clin Oncol 2009;Vol.27(15):abstr.1004.
  11. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44.
  12. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;Vol.28:1124-30.
  13. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-5.
  14. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52-8;discussion59-62.
  15. Garcia-Saenz JA, Martin M, Puente J, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005;6:325-9.
  16. Bartsch R, Wenzel C, Hussian D, et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 2006;6:63.
  17. Tokajuk P, Czartoryska-Arlukowicz B, Wojtukiewicz MZ, et al. Continuation of trastuzumab-based therapy beyond disease progression in metastatic breast cancer patients - a retrospective one center analysis. Eur J Cancer 2008;7(Suppl. 6):221:abstr.581.
  18. Metro G, Mottolese M, Di Cosimo S, et al. Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). J Clin Oncol 2007; 25(Suppl.):1066.
  19. Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol 2007;18(Suppl. 6):vi11-15.
  20. Cancello G, Montagna E, D'Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008;10:60.
  21. Fabi A, Metro G, Ferretti G, et al. Do HER-2 positivemetastatic breast cancer patients
  22. benefit from the use of trastuzumab beyond disease progression? Amono-institutional experience and systematic review of observational studies. Breast 2008; 7:499-505.
  23. Montemurro F, Faggiuolo R, Redana S, et al. Continuation of trastuzumab beyond disease progression [letter]. J Clin Oncol 2005;23:2866-8;discussion 2868-69.
  24. Antoine EC, Extra JM, Vincent-Salomon A, et al. Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: Results from the Hermine cohort study [abstract 2099]. Eur J Cancer 2007;43(Suppl. 5):213.
  25. Extra J-M, Antoine EC, Vincent-Salomon, et al. Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study. Oncologist 2010;15:799-809.
  26. Stemmler HJ, Kahlert S, Siekiera W, et al. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005;28:582-6.
  27. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumabbased therapy. Oncologist 2006; 11:318-24.
  28. Jackisch C Eustermann H, Schoenegg W, et al. Clinical use of trastuzumab (Herceptin) in metastatic breast cancer (MBC) in Germany from 2001 to 2006. Breast Cancer Res Treat 2007;106(Suppl. 1):186,abstr.4059.
  29. Campiglio M, Bufalino R, Sandri M, et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011;128(Suppl. 1):147-54.
  30. Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era [letter]. J Clin Oncol 2005;23:2114-16.
  31. Pinder M, Chang HY, Broglio KM, et al. Trastuzumab treatment and brain metastases in HER2-positive metastatic breast cancer. In Poster 1018 Presented at the 43rd ASCO Annual Meeting, Chicago, IL, 1-5 June 2007;abstr.1018.
  32. Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 2007;85:311-17.
  33. Church DN, Modgil R, Guglani S, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 2008;31:250-54.
  34. Brufsky AM, Mayer M, Rugo HS, et al. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clin Cancer Res 2011;17(Suppl. 14):4834-43.
  35. Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008;19:1242-8.
  36. Nam B-H, Kim SY, Han H-S et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008;10:20.
  37. Park IH, Ro J, Lee KS, et al. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009;20:56-62.
  38. Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2010;21:942-48.
  39. Vukelja S, Rugo H, Vogel S, et al. A phase II of trastuzumab-DM1, a first-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. Cancer Res 2009;69:71.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies